Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Hsu Untied Interview with Caine Moss, Partner at Goodwin (Hsu Untied Podcast)

main

announcements-lifesciences-hsu-untied-interview-partner-at-goodwin

Caine Moss, a partner in Goodwin's Technology group, was recently featured as a guest on Hsu Untied, a unique podcast with Richard Hsu.

Hsu Untied Interview with Caine Moss, Partner at Goodwin (Hsu Untied Podcast)

Related Content

The USPTO Proposes a Radical Change to Terminal Disclaimer Practice: You Have an Opportunity to Comment

Biogen’s TOFIDENCE (tocilizumab) Approved in the EU

FDA Issues Overdue Draft Guidance on Clinical Trial Diversity Action Plans

FDA Issues Overdue Draft Guidance on Clinical Trial Diversity Action Plans

UK General Election: Key Employment-Related Manifesto Pledges

Eculizumab BPCIA Litigation Update: Court Denies Alexion’s Motion for an Injunction Pending Appeal

Now Available! Announcing the Vaccine Patent Litigation and Vaccine Patent PTAB Trackers

Update on John Hopkins and Merck Pembrolizumab Litigation

ACS Webinar - Avoiding IP Own Goals in Drug Discovery: Best Practices for Obtaining (and Keeping) Your IP

Amid Ongoing Regional Growth, Goodwin Relocates Singapore Office

Entrada Therapeutics Closes $100 Million Registered Direct Offering

The Future of Non-Compete Agreements in America

UroMems raises €44 million in Series C Financing

Marea Therapeutics Launches with $190 Million Series A and Series B Financings

Antitrust Implications of State Regulators’ Increasing Scrutiny

The Legal 500 US 2024 Recognizes 44 Goodwin Practices and 187 Lawyers

Life Sciences

Technology